- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00389025
Mast-Cell Stabilizing Effects of Olopatadine
November 18, 2016 updated by: Alcon Research
To assess the effects of olopatadine of the release of mast cell histamine
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Padova, Italy
- Padova Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Asymptomatic and not using any topical or systemic medication
Exclusion Criteria:
- Age
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Tear histamine
|
Secondary Outcome Measures
Outcome Measure |
---|
Tear cytology, subject evaluation of ocular itching, investigators evaluation of ocular redness
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Terry Wiernas, Alcon Research
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2006
Primary Completion (Actual)
April 1, 2007
Study Registration Dates
First Submitted
October 13, 2006
First Submitted That Met QC Criteria
October 16, 2006
First Posted (Estimate)
October 17, 2006
Study Record Updates
Last Update Posted (Estimate)
November 22, 2016
Last Update Submitted That Met QC Criteria
November 18, 2016
Last Verified
January 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Hypersensitivity, Immediate
- Eye Diseases
- Hypersensitivity
- Conjunctival Diseases
- Conjunctivitis
- Conjunctivitis, Allergic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Anti-Allergic Agents
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Histamine H1 Antagonists, Non-Sedating
- Olopatadine Hydrochloride
Other Study ID Numbers
- C-05-30
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Conjunctivitis
-
Laboratoires TheaCompletedSeasonal Allergic ConjunctivitisFrance
-
Bausch & Lomb IncorporatedCompletedSeasonal Allergic ConjunctivitisSingapore
-
Bausch & Lomb IncorporatedCompletedSeasonal Allergic ConjunctivitisUnited States
-
Eleven BiotherapeuticsCompletedAllergic Conjunctivitis (AC)United States
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...CompletedSeasonal Allergic ConjunctivitisChina
-
NovartisAlcon ResearchCompletedSeasonal Allergic ConjunctivitisChina
-
Ocular Therapeutix, Inc.ORA, Inc.CompletedChronic Allergic Conjunctivitis
-
Ocular Therapeutix, Inc.ORA, Inc.CompletedChronic Allergic Conjunctivitis
-
ORA, Inc.CompletedChronic Allergic ConjunctivitisUnited States
-
Aciex Therapeutics, Inc.CompletedAtopic Disease (Including Allergic Conjunctivitis)United States
Clinical Trials on Olopatadine (generic name)
-
University of California, Los AngelesCompletedHypoxia | Bradycardia | Apnea of PrematurityUnited States
-
AstraZenecaCompletedAtrial FibrillationSweden, Hungary, Poland, Denmark, Finland, Netherlands, Norway, Germany
-
CrystalGenomics, Inc.UnknownSolid TumourKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Emory UniversityCompletedRadius; Fracture, Lower or Distal EndUnited States
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Novartis PharmaceuticalsActive, not recruitingImmune Thrombocytopenia (ITP) | Cold Agglutinin Disease (CAD)United States, Spain, Germany, Korea, Republic of, United Kingdom, Italy
-
Fundación Pública Andaluza para la gestión de la...Spanish Network for Research in Infectious DiseasesCompletedInfection Due to ESBL Escherichia ColiSpain
-
Vistakon PharmaceuticalsCompletedAllergic ConjunctivitisUnited States
-
Vistakon PharmaceuticalsCompletedAllergic ConjunctivitisUnited States